CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced the issuance of two United States patents covering its AUGMENTSM fertility treatment. AUGMENT is based on the Company’s egg precursor cell (EggPCSM) technology and is being developed to improve egg quality and the success of in vitro fertilization (IVF). AUGMENT will be available in international IVF clinics this year.
Help employers find you! Check out all the jobs and post your resume.
